In consultation: Guidance and quality standards
Showing 11 to 11 of 11
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [ID6168] | Final draft guidance | Technology appraisal guidance |